EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy

Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, Jizhou Tan, Ting Liu und 13 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202519574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Huixin Gao und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, P.R. China. Hauptthemen laut MEDLINE: Immunotherapy, B7-H1 Antigen, Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy of immunotherapy in enhancing antitumor immunity in solid tumors remains limited, primarily due to the insufficient immunogenicity of tumor cells. In contrast, vaccination and natural viral infections can generate durable, high‐titer antiviral antibodies. A modular Programmed Death‐Ligand 1 (PD‐L1)‐binding antigen presenter (PBAP) has been engineered to tether varicella‐zoster virus (VZV) glycoprotein E (gE) to PD‐L1 expressed on tumor cell surfaces. This innovative construct leverages pre‐existing anti‐gE antibodies to trigger antibody‐dependent effector mechanisms. PBAP‐gE effectively bound to PD‐L1 positive tumor cells and, together with vaccine‐induced anti‐gE antibodies, potentiated NK cell‐mediated antibody‐dependent cellular cytotoxicity (ADCC) in vitro and induced significant tumor regression in murine models. The PBAP platform is modular and versatile. For example, a PBAP‐HER2 construct synergized with Herceptin and Kadcyla to eliminate human epidermal growth factor receptor 2 (HER2)‐negative, PD‐L1 positive cells. This work represents an innovative strategy for enhancing PD‐L1‐targeted therapies by leveraging pre‐existing antibodies induced by vaccination or natural viral infections, alongside commercially available antibody‐based therapies. Given the broad expression of PD‐L1 across various solid tumors and hematologic malignancies, our strategy holds promise as a potentially widely applicable platform for diverse PD‐L1‐positive patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyB7-H1 AntigenNeoplasmsCancer VaccinesHumansAnimalsMice

Stichwörter der Autor:innen

PD‐L1 targeted immunotherapyPD‐L1‐binding antigen presenter (PBAP)antibody drug conjugates (ADC)antibody‐dependent cellular cytotoxicity (ADCC)vaccine‐induced antibodies

Substanzen

B7-H1 AntigenCancer VaccinesCD274 protein, human

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Guangzhou, Guangdong, P.R. China.
  • Department of Medical Oncology, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, P. R. China.
  • Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, P.R. China.
  • Department of Traditional Chinese Medicine, The Third People's Hospital of Hubei Province, Wuhan, Hubei, P.R. China.
  • The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, P.R. China.
  • The Second Clinical Medical College, Clinical Laboratory/State Key Laboratory of Traditional Chinese Medicine Syndrome, Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangz…

ORCID-Profile: Fan Zou

Förderung

  • Shenzhen Science and Technology Program
  • Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Doctor "Sailing" project of Science and Technology Department of Guangzhou
  • Sanming Project of Medicine in Shenzen Municipality
  • Shenzhen Science and Technology Innovation Program
  • National Natural Science Foundation of China

Zitieren

APA

Gao, H., Lu, L., Xiong, X., Li, Y., Hu, D., Zhang, D., Feng, Z., Liu, C., Liu, N., Li, X., Tan, J., Liu, T., Peng, L., Lu, L., Feng, H., Zhong, Y., Tan, G., Zhang, Z., Huang, L., …, & Zou, F. (2026). PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202519574

Vancouver

Gao H, Lu L, Xiong X, Li Y, Hu D, Zhang D, et al. PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy. Advanced Science. 2026. doi:10.1002/advs.202519574

BibTeX
@article{Gao2026,
  author = {Gao, Huixin and Lu, Lijuan and Xiong, Xiaoxiao and Li, Yi and Hu, Donghui and Zhang, Duo and Feng, Zhiwei and Liu, Cong and Liu, Nannan and Li, Xiaoli and Tan, Jizhou and Liu, Ting and Peng, Ling and Lu, Lu and Feng, Huiyi and Zhong, Yan and Tan, Guisen and Zhang, Zhicheng and Huang, Liqin and Su, Chao and Xue, Ying and Song, Shuo and Fan, Wenxia and Wang, Wei and Zou, Fan},
  title = {PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202519574}
}
Kostenlos starten →